Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...

Endogenex has raised $50 million in venture capital financing to complete the development of its minimally invasive procedure ...

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...

China’s BrightGene has served up a slice of early-stage data to remind everyone it has a horse in the oral obesity race.  | ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

Novo Nordisk and its Chinese partner have reported another midphase win for their triple-G candidate, sharing diabetes data ...

When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnim | Shionogi has ...

Following its curtain-raising at last fall’s meeting of the Radiological Society of North America, GE HealthCare has obtained ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...